Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Wave Life Sciences reported a quarterly loss of $0.32 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.30, but an improvement from a loss of $0.47 per share a year ago [1] - The company posted revenues of $7.61 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 41.25% [2] - Wave Life Sciences shares have declined approximately 36.5% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - The company has surpassed consensus EPS estimates only once in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.27, with expected revenues of $17.32 million, and for the current fiscal year, the estimate is -$1.16 on revenues of $43.83 million [7] Market Outlook - The stock currently holds a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Medical - Biomedical and Genetics industry is ranked in the top 36% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]